A growing body of research suggests a surprising benefit to a class of drugs initially developed for type 2 diabetes: potential protection against several types of stroke, including the often-fatal subarachnoid hemorrhage. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and liraglutide, are showing promise in reducing both the incidence and severity of stroke, according to studies leveraging large health databases.
The findings, published recently and building on earlier research, offer a potential new avenue for preventing and treating cerebrovascular events. While the exact mechanisms are still being investigated, researchers believe GLP-1 RAs may offer neuroprotective effects, reduce inflammation and improve blood vessel function. This is particularly noteworthy given the increasing prevalence of both diabetes and stroke worldwide.
A retrospective study utilizing data from the TriNetX database – encompassing years of patient records from 2014 to 2024 – revealed significant benefits for patients taking GLP-1 RAs after experiencing a subarachnoid hemorrhage (aSAH). Patients treated with these medications showed a 27% reduction in rebleeding (OR 0.73, p = 0.003) and a substantial 59% decrease in mortality (OR 0.41, p < 0.001) at six months post-diagnosis, according to research published in PubMed. These positive effects extended to one year, with lowered rates of cognitive deficits (OR 0.63, p = 0.034) and mortality (OR 0.39, p < 0.001).
Impact on Different Stroke Types
The protective effects weren’t limited to aSAH. The TriNetX data also indicated benefits for patients with spontaneous intracerebral hemorrhage (sICH) and acute ischemic stroke (AIS). For sICH patients, GLP-1 RA use was associated with decreased rates of hydrocephalus (OR 0.37, p = 0.005) and seizures (OR 0.56, p = 0.007) at six months, with similar improvements observed at one year. Mortality and rebleeding rates were also lower in this group (OR 0.45-0.40, and 0.70-0.69, respectively, both p < 0.001).
In patients experiencing an acute ischemic stroke, mortality fell significantly at both six months (OR 0.27, p < 0.001) and one year (OR 0.44, p < 0.001). Recurrence rates were also reduced (OR 0.60, p < 0.001), alongside lower rates of hydrocephalus (OR 0.32, p < 0.001) and seizures (OR 0.43, p < 0.001) at six months. Importantly, the study also showed a lower incidence of all three stroke types – aSAH, ICH, and AIS – at one and two years in GLP-1 RA users (ORs ranging from 0.62 to 0.87, all p < 0.05).
Beyond Treatment: Potential for Prevention
The research suggests a potential preventative role for GLP-1 RAs. The observed reductions in the incidence of stroke types at one and two years indicate that these medications may not only improve outcomes after a stroke but could also lower the risk of experiencing one in the first place. This is supported by findings from the American Heart Association, which highlighted the potential protective effect against nontraumatic subarachnoid hemorrhage in individuals with intracranial aneurysms.
Still, experts caution that these findings are observational and do not prove causation. Further research, including randomized controlled trials, is needed to confirm these benefits and determine the optimal use of GLP-1 RAs for stroke prevention and treatment. The study did note that adverse events were similar between those taking GLP-1 RAs and those who weren’t, offering some reassurance regarding safety.
What This Means for Patients
The implications of these findings are significant, particularly given the widespread use of GLP-1 RAs for managing type 2 diabetes and, increasingly, for weight loss. These medications, including exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, and tirzepatide, are becoming more accessible, and their potential neuroprotective effects add another layer to their therapeutic value. The European Medical Journal recently reported that GLP-1RAs are linked to reduced haemorrhagic stroke risk.
It’s crucial to emphasize that these medications should only be used under the guidance of a healthcare professional. The decision to prescribe a GLP-1 RA should be based on individual risk factors, medical history, and a careful assessment of potential benefits and risks. Patients currently taking these medications should continue to follow their doctor’s instructions and report any new or concerning symptoms.
Researchers are continuing to investigate the underlying mechanisms responsible for these observed benefits. Understanding how GLP-1 RAs protect the brain could lead to the development of even more targeted and effective stroke prevention strategies. The next step involves larger, more definitive clinical trials to validate these findings and establish clear guidelines for clinical practice.
Have questions about GLP-1s and stroke risk? Share your thoughts in the comments below, and please consider sharing this article with your network.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
